代谢异质性会影响HER2阳性晚期胃癌患者对trastuzumab的反应和存活率
Jun Wang1, Na Sun1, Thomas Kunzke1
1Research Unit Analytical Pathology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
在HER2阳性胃癌中代谢异质性预测对trastuzumab的反应. 更高的异质性与更好的预后和对这种向治疗的敏感性相关,为治疗策略提供了新的见解.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 癌症研究 癌症研究
背景情况:
- 特拉斯图祖马布是唯一针对HER2阳性晚期胃癌的人类表皮生长因子受体2 (HER2) 的一线治疗方法.
- 代谢异质性对trastuzumab疗效的影响尚不清楚.
研究的目的:
- 调查HER2-阳性晚期胃癌中代谢异质性和trastuzumab治疗反应之间的关联.
- 为了确定与治疗结果相关的潜在代谢亚群.
主要方法:
- 在治疗前活检上使用高质量分辨率成像质谱的空间代谢学.
- K-意味着聚类来分析代谢异质性并识别瘤亚群.
- 辛普森的多样性指数来量化代谢异质性的水平.
主要成果:
- 在HER2阳性胃癌患者中确定了代谢异质性,揭示了九种不同的瘤亚群.
- 较高的代谢异质性与trastuzumab敏感性有显著的相关性 (p=0.008),并显示出有利预后的趋势.
- 特定的子群体与良好的预后/trastuzumab敏感性或不良预后/耐药性有关.
结论:
- 通过组织代谢学评估的瘤代谢异质性与 HER2 阳性胃癌的预后和 trastuzumab 反应有关.
- 独特的瘤代谢亚群可以作为预测性生物标志物,用于特斯图祖马布治疗疗效.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
